Romiplostim to prevent low platelets in Ewing sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a platelet-boosting medicine called romiplostim to prevent dangerously low platelet counts caused by chemotherapy in children with newly diagnosed Ewing sarcoma. It is designed for patients who do not have cancer spread to the bone marrow and have not taken similar platelet drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Patient is older than 1 year
- Newly diagnosed with Ewing sarcoma and receiving standard intensive chemotherapy
- Cancer has not spread to the bone marrow
- Has not taken any platelet-boosting medicines before
- No history of bone marrow failure, blood cancer, clotting problems, or platelet disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests a drug called romiplostim to prevent low platelet counts (a condition that raises bleeding risk) caused by chemotherapy in people with breast cancer. If you qualify, you may receive this drug to help keep your platelets at a safer level during future treatments.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.